Investor Presentaiton
Strong performance
Revenue +11%, NPATA²,3 +13%, NPAT +20%
CSL Behring
Strong growth across the
portfolio especially Ig
lg +23%, KCENTRA® +12%,
Revenue
by Segment
HAEGARDA® +9%
•
Gross margin recovery underway
Seqirus
+2%
Good progress with plasma initiatives
Garadacimab filed
Behring
+14%
$8,053m
Vifor
nc4
•
CSL Seqirus
Solid performance in a
challenging season
FLUAD® +14%
Regulatory approval for world first sa-mRNA
COVID vaccine
aQIVc phase 3 - last patient enrolled Jan
2024
CSL Vifor
Well prepared for
transitioning Iron market
Successful TAVNEOS® EU launch
Strong patient conversion to MIRCERAⓇ
1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail..
2. NPATA is defined as the statutory net profit after tax before impairment and amortisation of acquired intellectual property, business acquisition and integration costs and unwind of the inventory fair value uplift
3. Attributable to the shareholders of CSL Limited
4. Not comparable
4
Driven by Our Promise
CSLView entire presentation